At the 2026 SCOPE Summit for Clinical Operations, one idea kept resurfacing: biospecimens are no longer treated as physical materials moving through a supply chain. They’re treated as data—and that reframes everything from protocol design to chain of custody to the quality systems we need to prove we can trust what we generate. Read three takeaways for biomarker operations, biospecimen operations, and clinical operations leaders who are trying to scale without taking on disproportionate risk.